MorphoSys AG: MorphoSys Presents Latest Data from the Phase

MorphoSys presents latest data from the Phase 2 MANIFEST Study evaluating the potential of pelabresib in the treatment of myelofibrosisData presented during poster and oral sessions at the 63rd American

Related Keywords

Germany , Georgia , United States , Munich , Bayern , Planegg , Atlanta , American , Srdan Verstovsek , Development Officer , Janssen Biotech Inc , American Society Of Hematology Annual Meeting , Drug Administration , Morphosys Group , Md Anderson Cancer Center , Constellation Pharmaceuticals Inc , Janssen Research Development , Morphosys Us Inc , Nasdaq , Exchange Commission , Constellation Pharmaceuticals , American Society , Hematology Annual Meeting , Malte Peters , Morphosys Chief Research , Cancer Center , Janssen Research , Janssen Biotech , Morphosy Annual Report , Morphosys , Presents , Latest , Data , Rom , Hase , Manifest , Study , Valuating , Potential , Pelabresib , Treatment , Myelofibrosis ,